Has Arthur Mabaquiao, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,597,990 in general payments to Arthur Mabaquiao, MD across 2,593 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Arthur Mabaquiao, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Arthur Mabaquiao, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Arthur Mabaquiao, MD

Rheumatology · San Diego, CANPI 1730271933

Payments from drug & device makers

$1,597,990in general payments, 2019–2025

Across 2,593 payments — averaging $616.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$414K
Amgen$294K
Regeneron$100K
Mesoblast, Inc.$100K
E.r. Squibb & Sons, L.L.C.$82K
Astrazeneca UK Limited$79K
plus $529K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	389	$413,666
Amgen(2 entities)	597	$294,473
Regeneron	16	$100,130
Mesoblast, Inc.	9	$99,601
E.r. Squibb & Sons, L.L.C.	33	$82,012
Astrazeneca UK Limited	10	$79,207
AstraZeneca(2 entities)	88	$68,162
Novartis	146	$59,568
Takeda Pharmaceuticals U.S.A., Inc.	24	$56,043
Biogen	3	$51,472
UCB, Inc.	203	$45,831
Pfizer	108	$45,474
GSK	130	$43,346
Eli Lilly	8	$38,218
Janssen Research & Development, LLC	5	$22,960
UCB SA	1	$17,408
Kiniksa Pharmaceuticals, Ltd.	30	$14,593
Gilead	2	$12,855
Mallinckrodt Enterprises LLC	27	$12,820
Actelion Pharmaceuticals US, Inc.	62	$8,782
Mallinckrodt Hospital Products Inc.	99	$5,562
Genentech, Inc.	3	$4,488
Kiniksa Pharmaceuticals International, PLC	3	$3,299
Ironwood Pharmaceuticals, Inc	2	$3,180
Johnson & Johnson	140	$2,692
Aurinia Pharma U.S., Inc.	55	$2,078
Boehringer Ingelheim	58	$1,731
ANI Pharmaceuticals, Inc.	53	$1,354
Lilly USA, LLC	53	$1,275
Genentech USA, Inc.	32	$698
Bristol Myers Squibb	15	$488
Sanofi	16	$484
Alnylam Pharmaceuticals Inc.	17	$461
Kyowa Kirin, Inc.	12	$422
Radius Health, Inc.	15	$394
Janssen Scientific Affairs, LLC	6	$298
CSL Behring	11	$240
Biocryst US Sales Co., LLC	8	$224
Eisai Inc.	10	$177
Medexus Pharma, Inc.	11	$172
Scilex Pharmaceuticals Inc.	8	$165
Lundbeck LLC	5	$129
Novo Nordisk	6	$123
Organon	5	$114
Bayer	6	$94
Arbor Pharmaceuticals, Inc.	6	$91
Pacira Therapeutics, Inc.	4	$87
Bioventus LLC	4	$75
Fresenius Kabi USA, LLC	3	$66
Fidia Pharma USA Inc.	3	$62
Octapharma USA, Inc.	2	$60
Sanofi-aventis U.S. LLC	3	$56
Hospira, Inc.	2	$55
Azurity Pharmaceuticals, Inc.	3	$50
Merck	2	$45
Grifols USA, LLC	2	$41
Shire North American Group Inc	2	$29
Avion Pharmaceuticals	2	$25
Vision Quest Industries Inc.	1	$25
Incyte Corporation	1	$22

How this compares

$1,597,990 in reported general payments places this provider in the 95th percentile of 808 rheumatology providers in California.

See all rheumatology providers in California →

Medicare billing

Part B allowed, 2024

$6,509,283

Medicare patients

587

Services billed

389,813

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other rheumatology in San Diego

Ara DikranianSan Diego$2.6M
Kenneth KalunianSan Diego$1.4M
Samy MetyasCovina$12.9M
Christine ThaiHuntington Beach$8.5M
Tien-I SuWhittier$8.4M
Eric LeeUpland$6.9M
Orrin TroumSanta Monica$6.9M
Shirley PangFullerton$5.7M
William RobinsonStanford$5.1M
Dan laTujunga$5.1M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →